Patient characteristics (N = 202)
| Characteristic . | n/N (%) . |
|---|---|
| Age, y | |
| Median | 70 |
| Range | 20-90 |
| WBC, × 109/L | |
| Median | 3 |
| Range | 1-77 |
| Platelets, × 109/L | |
| Median | 32 |
| Range | 2-321 |
| BM blasts, % | |
| Median | 32 |
| Range | 3-97 |
| t-AML | 52 (26) |
| s-AML | 30 (15) |
| Cytogenetics | |
| Complex | 166 (83) |
| Diploid | 17 (9) |
| Nondiploid, noncomplex | 17 (9) |
| Insufficient metaphases/not done | 2 (1) |
| No. of TP53 mutations | |
| 1 | 154 (76) |
| >1 | 48 (24) |
| TP53mutVAF, % | |
| Median | 43 |
| Range | 1-100 |
| TP53mutVAF, % | |
| ≤40 | 90 (45) |
| >40 | 112 (56) |
| TP53 loss | 93/200 (47) |
| Regimen | |
| Cytarabine based | 74 (37) |
| HMA based | 128 (63) |
| Regimen | |
| IDAC/HDAC | 45 (22) |
| LDAC | 29 (14) |
| HMA (no venetoclax) | 95 (47) |
| HMA plus venetoclax | 33 (16) |
| Characteristic . | n/N (%) . |
|---|---|
| Age, y | |
| Median | 70 |
| Range | 20-90 |
| WBC, × 109/L | |
| Median | 3 |
| Range | 1-77 |
| Platelets, × 109/L | |
| Median | 32 |
| Range | 2-321 |
| BM blasts, % | |
| Median | 32 |
| Range | 3-97 |
| t-AML | 52 (26) |
| s-AML | 30 (15) |
| Cytogenetics | |
| Complex | 166 (83) |
| Diploid | 17 (9) |
| Nondiploid, noncomplex | 17 (9) |
| Insufficient metaphases/not done | 2 (1) |
| No. of TP53 mutations | |
| 1 | 154 (76) |
| >1 | 48 (24) |
| TP53mutVAF, % | |
| Median | 43 |
| Range | 1-100 |
| TP53mutVAF, % | |
| ≤40 | 90 (45) |
| >40 | 112 (56) |
| TP53 loss | 93/200 (47) |
| Regimen | |
| Cytarabine based | 74 (37) |
| HMA based | 128 (63) |
| Regimen | |
| IDAC/HDAC | 45 (22) |
| LDAC | 29 (14) |
| HMA (no venetoclax) | 95 (47) |
| HMA plus venetoclax | 33 (16) |
BM, bone marrow; s-AML, secondary AML; t-AML, therapy-related AML; WBC, white blood cell count.